BR112022019018A2 - COMPOSITION INCLUDING FIBER AND CRANBERRY - Google Patents

COMPOSITION INCLUDING FIBER AND CRANBERRY

Info

Publication number
BR112022019018A2
BR112022019018A2 BR112022019018A BR112022019018A BR112022019018A2 BR 112022019018 A2 BR112022019018 A2 BR 112022019018A2 BR 112022019018 A BR112022019018 A BR 112022019018A BR 112022019018 A BR112022019018 A BR 112022019018A BR 112022019018 A2 BR112022019018 A2 BR 112022019018A2
Authority
BR
Brazil
Prior art keywords
cranberry
fiber
composition including
including fiber
component
Prior art date
Application number
BR112022019018A
Other languages
Portuguese (pt)
Inventor
Dong Zhizhong
Shi Yujie
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of BR112022019018A2 publication Critical patent/BR112022019018A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Materials For Medical Uses (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)

Abstract

COMPOSIÇÃO QUE COMPREENDE FIBRA E AMORA. A presente invenção refere-se a uma preparação combinada de fibra e um componente de amora, bem como uma composição que compreende a preparação combinada como um componente ativo, seu uso e métodos de uso das mesmas, para controlar a resposta à glicose sanguínea, aumentar a perda de peso e/ou reduzir o ganho de massa gorda. A fibra e o componente de amora potencializam mutuamente ou interagem de modo sinérgico para realizar os usos acima.COMPOSITION INCLUDING FIBER AND CRANBERRY. The present invention relates to a combined preparation of fiber and a cranberry component, as well as a composition comprising the combined preparation as an active component, their use and methods of using them, for controlling blood glucose response, increasing weight loss and/or reduce fat mass gain. The fiber and cranberry component mutually enhance or interact synergistically to accomplish the above uses.

BR112022019018A 2020-04-24 2021-04-23 COMPOSITION INCLUDING FIBER AND CRANBERRY BR112022019018A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020086705 2020-04-24
PCT/EP2021/060663 WO2021214292A1 (en) 2020-04-24 2021-04-23 Composition comprising fibre and mulberry

Publications (1)

Publication Number Publication Date
BR112022019018A2 true BR112022019018A2 (en) 2022-11-01

Family

ID=75728811

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019018A BR112022019018A2 (en) 2020-04-24 2021-04-23 COMPOSITION INCLUDING FIBER AND CRANBERRY

Country Status (8)

Country Link
US (1) US20230218697A1 (en)
EP (1) EP4138873A1 (en)
JP (1) JP2023522579A (en)
CN (1) CN115379846A (en)
AU (1) AU2021258478A1 (en)
BR (1) BR112022019018A2 (en)
CA (1) CA3170830A1 (en)
WO (1) WO2021214292A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023165856A1 (en) * 2022-03-02 2023-09-07 Société des Produits Nestlé S.A. Use of a composition for managing postprandial glucose response and associated disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100623210B1 (en) * 2006-03-21 2006-09-12 주식회사 글루칸 A composition for the treatment of metabolic syndrome comprising beta-glucan and folium mori extracts as effective ingredients
WO2013078658A1 (en) 2011-12-01 2013-06-06 Nestec S.A. Morus berries and avoiding glucose peaks
KR101326002B1 (en) * 2012-02-02 2013-11-07 배용석 Composition for use of reducing and controlling blood glucose for improving diabetes
US11071767B2 (en) * 2014-04-13 2021-07-27 Marmar Investment Sp. Z O.O. Dietary compositions for reducing blood glucose levels and for weight management
CN104473152A (en) 2014-11-19 2015-04-01 石泽 Biological medicated food equivalent to acarbose physical method for reducing postprandial blood sugar
CN104666427A (en) 2015-02-11 2015-06-03 唐泽光 Method for extracting main active components of folium mori
KR101778227B1 (en) * 2016-08-16 2017-09-14 강원대학교산학협력단 Composition for anti-obesity comprising extract of Morus alba as effective component
CN106728868A (en) * 2016-12-28 2017-05-31 陕西红顶名医堂药业有限公司 Chinese medicine composition and preparation method thereof for treating diabetes
KR101949153B1 (en) * 2018-08-13 2019-02-18 충남대학교산학협력단 A pharmaceutical composition comprising viscozyme treated extract of Morus alba leaves for preventing or treating diabetes mellitus
CN110101747A (en) * 2019-06-13 2019-08-09 南京中医药大学 Application of the mulberry leaf active component composition in the drug or health care product of preparation prevention and treatment type II diabetes lesions of liver and kidney
CN110693028A (en) * 2019-10-25 2020-01-17 陕西中鸿科瑞再生医学研究院有限公司 Composition for reducing blood sugar and fat
CN111000949A (en) * 2019-12-17 2020-04-14 湖南橘色科技有限责任公司 Composition for improving subcutaneous fat type obesity and preparation method thereof

Also Published As

Publication number Publication date
EP4138873A1 (en) 2023-03-01
AU2021258478A1 (en) 2022-09-22
WO2021214292A1 (en) 2021-10-28
JP2023522579A (en) 2023-05-31
US20230218697A1 (en) 2023-07-13
CA3170830A1 (en) 2021-10-28
CN115379846A (en) 2022-11-22

Similar Documents

Publication Publication Date Title
BR112022001947A2 (en) RNA COMBINATIONS AND COMPOSITIONS WITH REDUCED IMMUNOSTIMULATORY PROPERTIES
BR112015010203A8 (en) composition for the prevention or treatment of diabetes, diabetic complications or diabetes, use of an oxytomodulin analog conjugate, and method for the preparation of an oxytomodulin analog conjugate
BR112022022331A2 (en) METHOD TO ENHANCE POSITIVE THERAPEUTIC EFFECTS OF A PSYCHEDELIC, COMPOSITION, AND METHOD TO TREAT A PATIENT
BR112017021311A2 (en) pharmaceutical compositions for combination therapy
BR112019008458A2 (en) 1,2,4-triazolones 2,4,5-trisubstituted.
BR112017012327A2 (en) 1,3-thiazol-2-yl substituted benzamides.
BR112017017888A2 (en) fluorinated derivatives of tetrahydronaphthyridinyl nonanoic acid derivatives and uses of these
BR112022019057A2 (en) SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION
BR112014027571A2 (en) Methods for the treatment of diabetic retinopathy and other eye diseases
BR112013032265A2 (en) continuous subcutaneous insulin infusion methods with a hyaluronan degradation enzyme
BR112018016341A2 (en) catheter block solution and catheter block therapy
BR112023005377A2 (en) STABLE FORMULATIONS OF PROGRAMMED DEATH 1 (PD-1) RECEPTOR ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF, AND METHODS OF USE THEREOF
BR112018009941A8 (en) plant growth regulatory composition with synergistic effect
BR112015019039A8 (en) fluorinated integrin antagonist compounds, a pharmaceutical composition comprising said compounds and their use to treat or prevent an av integrin mediated disease or condition
BR112017020132A2 (en) methods for promoting hair growth or preventing hair loss in an individual and for preparing a composition, and,
BR112022019018A2 (en) COMPOSITION INCLUDING FIBER AND CRANBERRY
CL2019001586A1 (en) Insulin containing pharmaceutical compositions.
BR112021013415A2 (en) Multifunctional fusion proteins and uses thereof
BR112021024325A2 (en) 3-(5-Methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide analogues
BR112018074334A2 (en) use of mesenchymal stem cells and parts thereof
BR112016016153A2 (en) enolase 1 (eno1) compositions and uses thereof
BR112022021370A2 (en) COMPOUND AND METHOD OF TREATMENT OF A DISEASE OR DISORDER
CO2021013251A2 (en) Glucose-sensitive insulin derivatives
BR112022015579A2 (en) COMPOSITIONS FOR TREATMENT OF EYE DISEASES
BR112023001924A2 (en) BENZIMIDAZOLE DERIVATIVES, METHOD OF PREPARATION AND MEDICAL USE OF THEM